Recently, Chemical.AI, a research and development technology company that empowers chemistry with AI, announced a strategic partnership agreement with CarbonSilicon AI, a technology company that focuses on AI-driven new drug research and development. This partnership will be based on Chemical.AI's AI-enabled retrosynthesis technology platform and CarbonSilicon AI's drug design platform, jointly promoting AI-driven drug design full-process closed-loop and carrying out innovative project collaboration in AI modeling, lead drug design, and retrosynthesis, etc., so as to improve the efficiency of drug development . The two parties will cooperate at both the technical and commercial levels to jointly provide customers with drug design and retrosynthesis software products, as well as drug design and synthesis services based on advanced computing technologies, helping customers significantly reduce the R&D cycle and improve the R&D success rate.

“Artificial intelligence will bring new potential and opportunities for China's pharmaceutical industry. Said Dr. Ning Xia, founder and CEO of Chemical.AI. By empowering drug development through AI, we can effectively improve efficiency and save costs at all stages of pharmaceutical R&D. We are pleased to join hands with CarbonSilicon AI to leverage their strengths in jointly solving the difficulties and pain points in the process of new drug development. This will further empower new drug research and development, improve the output efficiency of the industry, accelerate the speed of drug research and development, and establish a win-win business model."

Yafeng,Deng, founder and CEO of CarbonSilicon AI, said, "Recently, artificial intelligence technology has made rapid progress. Pre-trained models, AIGC and other technologies have made significant progress in the fields of molecular generation, docking, drug efficacy prediction, and retrosynthesis, gradually changing the efficiency and success rate of new drug research and development. CarbonSilicon AI and Chemical.AI have joined forces, playing to their respective strengths, cooperating for mutual benefit, and working together in the early drug discovery and reverse synthesis fields, which will help accelerate the speed of drug development and improve industry research and development efficiency. We hope to empower industry partners better together with Chemical.AI."

About CarbonSilicon AI

CarbonSilicon AI is a technology company focusing on new drug development. Our positioning is as an artificial intelligence infrastructure and service provider in the field of new drug development. We aim to deeply integrate advanced life science technology with information science technology such as artificial intelligence. In the area of new drug research and development, we utilize advanced artificial intelligence technologies such as deep generation (AIGC), self-supervised pre-training, and reinforcement learning. In addition, we deeply integrate physical computing and software and hardware automation technologies, and improve the production data, management data, and AI modeling capabilities in the field of new drug research and development. We digitize and intelligence the various stages of new drug development, form a closed-loop of dry and wet experimental data, and solve the problem of new drug development.

www.carbonsilicon.ai

About Chemical.AI

Chemical.AI was founded in 2018 as an AI-enabled chemical research and development technology company. By using artificial intelligence and chemical big data, we have developed efficient chemical research tools and are committed to shaping the future of chemistry. Our core product, the ChemAIRS,a retrosynthetic route design software, improves synthetic route design and predicts success rates through diverse synthesis strategies. In 2021, we established the ChemAILab, automated laboratory in Shanghai, which utilizes AI, big data, and robotics to provide professional and efficient chemical synthesis services to our clients. Our independently developed ChemAIoTtechnology achieves algorithmic decision-making intelligence, standardized workflow processes, high-quality data barriers, and human-machine collaborative automatic synthesis. Meanwhile, ChemAIOS is our independently developed laboratory intelligent management system that provides a one-stop operation platform for production and research. We have successfully provided technical services to multiple well-known domestic and foreign pharmaceutical companies and CROs and have established deep cooperation with them.

www.chemical.ai